Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro-Reference-Cited by-同舟云学术

Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro

Published:2018-12 Issue: Volume:126 Page:149-155
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Nishino Masaya^ORCID,Suda Kenichi,Kobayashi Yoshihisa,Ohara Shuta,Fujino Toshio,Koga Takamasa,Chiba Masato,Shimoji Masaki,Tomizawa Kenji,Takemoto Toshiki,Mitsudomi Tetsuya

Funder

Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Boehringer-Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny;Suda;Cancer Metastasis Rev.,2012

2. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients;Wu;Oncotarget,2016

3. Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies;Campo;J. Thorac. Oncol.,2016

4. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin. Cancer Res.,2013

5. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N. Engl. J. Med.,2017

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report;Medicine;2024-07-12

2. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25

3. Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach;Exploration of Targeted Anti-tumor Therapy;2024-05-17

4. From osimertinib to preemptive combinations;Oncotarget;2024-03-15

5. What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors;Translational Lung Cancer Research;2024-02